Previous 10 | Next 10 |
Total Revenue up 51% and Product Revenue up 135% YOY 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enablin...
REDWOOD CITY, Calif. and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular Assemblies, Inc. , a pioneer in the field of enzymatic DNA synthesis, today announced the...
Codexis displays a weak affinity to the current premia investors are paying a premium for in FY22. Whilst top-line volumes continue to grow, bottom-up fundamentals also continue to weaken. ROIC and operating profit are also headwinds as capital markets begin to see higher costs of...
Codexis ( NASDAQ: CDXS ) appoints Dr. Stephen Dilly, former CEO of Sierra Oncology and current Codexis Board member, as the company’s President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons but will...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
Stocks finished higher on Friday, bouncing back after a downdraft that dominated most of the past several days. The gains came amid renewed confidence that the Federal Reserve would stick with the expected 75-basis-point rate hike at its next policy meeting, rather than resorting to a full-...
Gainers: NexImmune ( NEXI ) +34% . Allogene Therapeutics ALLO +12% . SOPHiA GENETICS ( SOPH ) +12% . Verona Pharma ( VRNA ) +8% . R1 RCM ( RCM ) +7% . Losers: Codexis ( CDXS ) -43% . 10x Genomics ( TXG ...
Codexis ( CDXS ) -23% as forecast comes below estimates . 10x Genomics ( TXG ) -19% on guiding Q2 revenues below consensus . Innovative Industrial Properties ( IIPR ) -21% . Lantern Pharma ( LTRN ) -10% . Sunrun ( RUN ) -8%...
ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...
Codexis ( NASDAQ: CDXS ) on Thursday said it had inked a deal with Pfizer ( PFE ) to make an enzyme used to manufacture nirmatrelvir, which is an active pharmaceutical ingredient in the U.S. drug giant's COVID-19 antiviral pill Paxlovid. In an separate 8-K filing w...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...